ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
7.09
-0.24 (-3.21%)
At close: Nov 18, 2025, 4:00 PM EST
7.25
+0.16 (2.31%)
Pre-market: Nov 19, 2025, 8:59 AM EST
ARS Pharmaceuticals Revenue
ARS Pharmaceuticals had revenue of $32.50M in the quarter ending September 30, 2025, with 1,471.62% growth. This brings the company's revenue in the last twelve months to $142.77M, up 5,459.66% year-over-year. In the year 2024, ARS Pharmaceuticals had annual revenue of $89.15M with 297,063.33% growth.
Revenue (ttm)
$142.77M
Revenue Growth
+5,459.66%
P/S Ratio
4.87
Revenue / Employee
$892,325
Employees
160
Market Cap
700.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89.15M | 89.12M | 297,063.33% |
| Dec 31, 2023 | 30.00K | -1.29M | -97.72% |
| Dec 31, 2022 | 1.32M | -4.19M | -76.10% |
| Dec 31, 2021 | 5.51M | -12.33M | -69.13% |
| Dec 31, 2020 | 17.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRY News
- 8 days ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating - Seeking Alpha
- 9 days ago - ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) - GlobeNewsWire
- 15 days ago - ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) - GlobeNewsWire
- 15 days ago - UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - GlobeNewsWire
- 16 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results - GlobeNewsWire
- 16 days ago - ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - GlobeNewsWire
- 6 weeks ago - ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - GlobeNewsWire